Themis raises 40 mln euros
Themis said Sept. 18 that it raised 40 million euros ($44 million) in a Series D round of funding co-led by new investors, Farallon Capital and Hadean Ventures. MSD (tradename of Merck & Co Inc, Kenilworth NJ USA) and Adjuvant Capital, as well as current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences, also participated. Themis develops immunomodulation therapies for infectious diseases and cancer.
18 September 2019•4 mins read
